AmerisourceBergen Increases Dividend 33 Percent and Authorizes a New $500 Million Share Repurchase Program

VALLEY FORGE, Pa.--(Business Wire)--
The Board of Directors of AmerisourceBergen Corporation (NYSE:ABC) today
increased the Company`s quarterly dividend rate 33 percent to $0.08 per common
share from $0.06 per common share. The Board of Directors also authorized a new
$500 million share repurchase program, effective immediately. The Company will
use the new program to repurchase its outstanding shares of common stock,
subject to market conditions.

R. David Yost, AmerisourceBergen President & Chief Executive Officer, said, "We
have again increased our dividend and authorized a new share repurchase program,
illustrating our continued confidence in delivering long-term shareholder
value."

The new repurchase program, combined with $68.1 million remaining on the
November 13, 2008 repurchase program, provides AmerisourceBergen with $568.1
million currently authorized for the repurchase of common shares.
AmerisourceBergen expects to spend approximately $350 million to repurchase its
common shares in fiscal year 2010. The Company currently has approximately 288
million common shares outstanding.

AmerisourceBergen may repurchase its shares from time to time for cash in open
market transactions or by other means in accordance with applicable federal
securities laws, and will hold any repurchased shares as treasury shares, which
will be available for general corporate purposes.

The quarterly dividend of $0.08 per common share will be payable December 7,
2009, to stockholders of record at the close of business on November 23, 2009.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies, with operations primarily in the United States and Canada. Servicing
both healthcare providers and pharmaceutical manufacturers in the pharmaceutical
supply channel, the Company provides drug distribution and related services
designed to reduce costs and improve patient outcomes. AmerisourceBergen's
service solutions range from pharmacy automation and pharmaceutical packaging to
reimbursement and pharmaceutical consulting services. With more than $71 billion
in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 10,000 people. AmerisourceBergen is ranked #26 on the
Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release contains forward-looking statements about AmerisourceBergen`s
future business and financial performance, estimates and prospects. These
statements are based on management`s current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary materially
from the expectations contained in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from
those described in any forward-looking statements: changes in pharmaceutical
market growth rates; the loss of one or more key customer or supplier
relationships; changes in customer mix; customer delinquencies, defaults or
insolvencies; supplier defaults or insolvencies; changes in pharmaceutical
manufacturers` pricing and distribution policies or practices; adverse
resolution of any contract or other dispute with customers or suppliers; federal
and state government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled substances; qui
tam litigation for alleged violation of laws and regulations governing the
marketing, sale and purchase of pharmaceutical products; changes in U.S.
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare; changes in
regulatory or clinical medical guidelines and/or labeling for the
pharmaceuticals we distribute, including certain anemia products; price
inflation in branded pharmaceuticals and price deflation in generics;
significant breakdown or interruption of our information technology systems; our
inability to implement an enterprise resource planning (ERP) system to handle
business and financial processes within AmerisourceBergen Drug Corporation`s
operations and our corporate functions without operating problems and/or cost
overruns; success of integration, restructuring or systems initiatives; interest
rate and foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom and
elsewhere outside of the United States, including potential changes in Canadian
provincial legislation affecting pharmaceutical product pricing or service fees
or regulatory action by provincial authorities in Canada to lower pharmaceutical
product pricing or service fees; the impact of divestitures or the acquisition
of businesses that do not perform as we expect or that are difficult for us to
integrate or control; our inability to successfully complete any other
transaction that we may wish to pursue from time to time; changes in tax
legislation or adverse resolution of challenges to our tax positions; increased
costs of maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; continued volatility, and further deterioration
of the capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally.Our most recent annual report on Form 10-K, quarterly reports on Forms
10-Q and current reports 8-K (which we may revise or supplement in future
reports filed to the SEC) provide additional information about these risks,
uncertainties and other matters. We do not undertake to update our
forward-looking statements.

AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com

Copyright Business Wire 2009